Rheumatoid arthritis (RA) is a complex, chronic autoimmune disease that affects ∼1% of the adult population worldwide ([@b1]). In addition to inflammation of the synovial joints, RA is characterized by systemic inflammation and the presence of serum autoantibodies against citrullinated peptides (anti--citrullinated protein antibodies \[ACPAs\]), as defined by positive findings on the anti--cyclic citrullinated peptide (anti-CCP) antibody test ([@b2]). Genome-wide association studies have been successful in determining many loci associated with complex diseases, including RA ([@b3]). The utility of susceptibility variants within single genetic loci, in isolation, is likely to be limited, with evidence emerging that linking multiple associated genes in pathways will lead to the better understanding of differing disease mechanisms ([@b4],[@b5]). To achieve robust pathway analysis, a comprehensive list of associated loci must be defined. Currently, 46 loci have been confirmed to be associated with RA susceptibility in Caucasians, at accepted levels of genome-wide significance (*P* \< 5 × 10^−8^), including 14 loci newly identified in a recent high-density, fine-mapping (ImmunoChip) study of RA ([@b6]).

In studies of inflammatory bowel disease (IBD), the findings have become much more informative, implicating risk pathways that have not been previously recognized as important to this disease, and thus increasing the number of susceptibility markers from 92 to 163. The increased number of susceptibility loci for IBD has also enabled much more informative investigation of disease overlap. Genetic studies of RA to date, albeit successful, have not yet delivered validated evidence of novel pathways. Moreover, disease overlap studies have been limited, thus emphasizing the continuing need for discovery of disease susceptibility markers in RA.

RA is currently divided into 2 groups based on serologic subtypes, which are defined according to the presence or absence of anti-CCP antibodies, although it is still unclear whether there are biologic pathways that are common or distinct to each group ([@b2]). Determining the genetic predisposition to each serologic subtype has the potential to better define the mechanism underlying each form of disease, enabling progress toward more focused clinical management.

The most recent study aimed at identifying RA susceptibility loci ([@b6]) used a custom Illumina array (ImmunoChip), designed to interrogate 196,524 single-nucleotide polymorphisms (SNPs) for 186 loci that have been previously shown to be associated with a number of autoimmune diseases. The study by Eyre and colleagues was the first to be powered to analyze the subgroups of seronegative RA and seropositive RA separately. Genotyping in 11,475 RA cases and 15,870 controls provided evidence for 14 novel SNPs that achieved genome-wide significance, with a further 16 SNPs putatively associated with RA in a second tier of significance (*P* = 5 × 10^−5^ \< 5 × 10^−8^), either in an unstratified analysis or in stratified analyses of the anti-CCP antibody subgroups. We therefore tested the 16 SNPs for which there was suggestive evidence of association with RA risk in 2 independent cohorts, comprising 6,106 RA cases and 4,290 controls, and performed a meta-analysis in which we combined our results with existing data to enhance the power to identify associations in the whole data set and in subgroups stratified by anti-CCP antibody status.

PATIENTS AND METHODS
====================

ImmunoChip discovery cohort
---------------------------

The characteristics of the patients in the original ImmunoChip discovery cohort (from the UK Rheumatoid Arthritis Consortium International \[RACI\]), as well as the genotyping and quality control procedures used for the ImmunoChip analysis, have been previously described ([@b6]). Individual-level data were available for each participant, and these data were used in the present analysis.

Validation cohorts
------------------

### UK cohort

The UK Rheumatoid Arthritis Group (UKRAG) cohort of patients with RA was recruited from 6 centers across the UK (Table[1](#tbl1){ref-type="table"}), as previously described ([@b7]). Genotyping was performed using the Sequenom platform.

###### 

Distribution of rheumatoid arthritis (RA) cases and controls in the ImmunoChip discovery cohort and the 2 validation cohorts[\*](#tf1-1){ref-type="table-fn"}

  Collection           RA cases   Controls                            
  -------------------- ---------- ---------- ------- ------- -------- ----
  ImmunoChip                                                          
   US                  2,536      75         1,803   593     2,134    65
   Swedish EIRA        2,762      70         1,762   987     1,940    73
   Swedish Umea        852        70         524     242     963      69
   Dutch               648        66         330     301     2,004    42
   Spanish             807        74         397     216     399      65
   UK                  3,870      74         2,406   1,000   8,430    53
   Total               11,475     72         7,222   3,339   15,870   61
  Validation                                                          
   CORRONA/I2B2 (US)   2,206      78         1,410   446     1,863    75
   UKRAG (UK)          3,900      73         536     274     2,427    74
   Total               6,106      76         1,946   720     4,290    75
  Combined             17,581     73         9,168   4,059   20,160   65

\* Except where indicated otherwise, values are the number of participants. Anti-CCP = anti--cyclic citrullinated peptide; EIRA = Epidemiological Investigation of Rheumatoid Arthritis; CORRONA = Consortium of Rheumatology Researchers of North America; I2B2 = Informatics for Integrating Biology and the Bedside; UKRAG = UK Rheumatoid Arthritis Group.

### US cohort

Samples from patients with RA in the US Consortium of Rheumatology Researchers of North America (CORRONA) collection and Informatics for Integrating Biology and the Bedside (I2B2) program were also tested using the ImmunoChip custom genotyping SNP array (Table[1](#tbl1){ref-type="table"}). Principal components analysis was performed using the EigenSoft program (version 29) with HapMap phase III samples, to exclude individuals of non-European ancestry. To check relatedness between the CORRONA/I2B2 samples and the RACI ImmunoChip samples, estimates of identity-by-descent and identity-by-state allele-sharing proportions were performed in Plink, using a set of SNPs selected for high quality (missingness *P* \< 0.002, minor allele frequency \[MAF\] \>0.1) and pruned for LD (r^2^ \< 0.2; samples were removed if the PI_HAT value was \>0.2 \[n = 1 sample per pair\]).

SNP selection/prioritization
----------------------------

Sixteen SNPs were selected for genotyping, based on suggestive evidence of a significant association with RA susceptibility (*P* \> 5 × 10^−8^ to *P* \< 5 × 10^−5^) in either the overall ImmunoChip genotyping analysis or in subgroups defined by the presence or absence of anti-CCP antibodies. Seven SNPs were selected from the full ImmunoChip cohort, 5 from the anti-CCP--positive subgroup, and 4 from the anti-CCP--negative subgroup.

Statistical analysis
--------------------

### Stage one: validation analysis

SNPs were included in the validation analysis if they passed quality control in both the UKRAG and US cohorts. Samples or SNPs with a call rate of \<98% were removed. In addition, SNPs that did not conform to Hardy-Weinberg equilibrium (*P* \< 5 × 10^−7^) as well as SNPs with differential missingness (*P* \> 0.01) or an MAF \<0.01 were also removed. After applying all of the quality control filters, 4 SNPs (from 944 RA cases \[20%\] and 244 controls \[9%\]) failed quality control.

We tested for the association of each SNP with RA in each study independently, using logistic regression under an additive model, and then combined the results in a fixed-effects meta-analysis with inverse variance weighting (performed in Plink). The top 10 principal components were incorporated as covariates in the logistic regression analysis of the US CORRONA data set, to correct for population stratification. *P* values less than 0.05 were considered as evidence of a significant association in the validation cohorts.

### Stage two: meta-analysis of ImmunoChip and validation data

The association of each SNP with RA in the original ImmunoChip analysis and in the validation analysis was tested in a fixed-effects meta-analysis with inverse variance weighting (performed in Plink). A *P*~meta-analysis~ threshold of less than 5 × 10^−8^ was considered significant, i.e., indicative of the discovery of a novel RA risk gene. All *P* values reported are 2-tailed. Heterogeneity between studies was assessed using Cochran\'s Q statistic test and the I^2^ test. A *P* value for heterogeneity of less than 0.05 is suggestive of heterogeneity. The I^2^ test estimates the extent of heterogeneity and takes values between 0% and 100%. I^2^ values of 0--25% indicate low heterogeneity, 25--50% moderate heterogeneity, 50--75% high heterogeneity, and 75--100% extreme heterogeneity ([@b8]).

### Anti-CCP subset analysis

In separate analyses of the data from the validation study and the data from the meta-analysis, we compared associations of all SNPs between controls and either anti-CCP--positive or anti-CCP--negative RA patients. In the validation study, there were 1,946 anti-CCP--positive RA patients, 720 anti-CCP--negative RA patients, and 4,290 controls. For the meta-analysis, there were 9,169 anti-CCP--positive RA patients, 4,059 anti-CCP--negative RA patients, and 20,160 controls.

### Power calculations

All power calculations were undertaken using Quanto. The model assumed was a log additive model, and population baseline risk estimate was 1%.

RESULTS
=======

In the validation analysis, 6 loci showed an association with RA susceptibility that reached significance (*P* \< 0.05): *COG6*, *PVT1, PTPN2*, *TNFSF4*, *RAD51B*, and *BACH2* (Table[2](#tbl2){ref-type="table"}). In the meta-analysis, 2 SNPs achieved genome-wide significance levels (*P*~meta-analysis~ \< 5 × 10^−8^): *BACH2* in the full meta-analysis ([Figure 1](#fig01){ref-type="fig"}A), and *RAD51B* in the anti-CCP--positive subgroup ([Figure 1](#fig01){ref-type="fig"}B). These findings in the meta-analysis indicate that *BACH2* and *RAD51B* are novel validated RA risk alleles. For the remaining SNPs, all effect sizes were in the same direction as in the original ImmunoChip analysis.

###### 

Associations of single-nucleotide polymorphisms (SNPs) with rheumatoid arthritis susceptibility in the ImmunoChip discovery cohort, validation cohorts, and meta-analysis[\*](#tf2-1){ref-type="table-fn"}

  Chr   SNP                                          Position (hg19)   Gene     Minor allele   ImmunoChip     Validation   Meta-analysis                                                                     
  ----- -------------------------------------------- ----------------- -------- -------------- -------------- ------------ --------------- ------ -------------- ------ -------------- ------ -------------- ------
  1     rs61828284[‡](#tf2-3){ref-type="table-fn"}   173,299,743       TNFSF4   A              5.5 × 10^−6^   0.83         0.01            0.81   1.5 × 10^−5^   0.88   2.1 × 10^−7^   0.82   0.48           0.97
  2     rs888427[§](#tf2-4){ref-type="table-fn"}     172,368,120       CYBRD1   A              5.2 × 10^−5^   1.12         0.76            1.02   0.00021        1.06   0.017          1.05   1.6 × 10^−4^   1.1
  3     rs1875463[¶](#tf2-5){ref-type="table-fn"}    143,165,502       SLC9A9   A              1.5 × 10^−6^   0.90         0.69            0.99   2.0 × 10^−5^   0.92   1.2 × 10^−4^   0.92   8.7 × 10^−5^   0.89
  6     rs72928038[¶](#tf2-5){ref-type="table-fn"}   90,976,768        BACH2    A              8.2 × 10^−7^   1.13         0.004           1.11   1.1 × 10^−8^   1.12   8.5 × 10^−6^   1.12   2.5 × 10^−4^   1.13
  7     rs59472144[¶](#tf2-5){ref-type="table-fn"}   37,369,908        ELMO1    A              3.5 × 10^−6^   1.12         0.78            1.01   5.1 × 10^−5^   1.09   9.3 × 10^−5^   1.10   0.04           1.07
  8     rs6651252[¶](#tf2-5){ref-type="table-fn"}    129,567,181       PVT1     G              2.0 × 10^−5^   0.89         0.004           0.88   2.4 × 10^−7^   0.89   5.3 × 10^−5^   0.89   0.001          0.88
  9     rs7857530[§](#tf2-4){ref-type="table-fn"}    102,747,941       TXNDC4   G              2.5 × 10^−5^   0.89         0.94            1.00   0.022          0.96   0.40           0.98   1.7 × 10^−4^   0.91
  13    rs7993214[‡](#tf2-3){ref-type="table-fn"}    40,350,912        COG6     A              4.6 × 10^−6^   0.90         0.05            0.92   9.1 × 10^−7^   0.92   6.0 × 10^−7^   0.9    0.15           0.96
  13    rs17230016[¶](#tf2-5){ref-type="table-fn"}   82,338,338        SPRY2    G              9.6 × 10^−6^   0.88         0.56            0.97   4.7 × 10^−5^   0.91   0.003          0.92   0.001          0.88
  14    rs911263[‡](#tf2-3){ref-type="table-fn"}     68,753,593        RAD51B   G              2.3 × 10^−6^   0.89         0.005           0.88   4.0 × 10^−5^   0.93   4.0 × 10^−8^   0.89   0.44           0.98
  17    rs8074003[¶](#tf2-5){ref-type="table-fn"}    76,364,493        SOCS3    A              1.4 × 10^−5^   0.81         0.44            0.95   9.2 × 10^−5^   0.86   1.9 × 10^−3^   0.86   9.2 × 10^−4^   0.80
  18    rs62097857[¶](#tf2-5){ref-type="table-fn"}   12,857,758        PTPN2    A              4.5 × 10^−6^   1.22         0.01            1.20   1.4 × 10^−7^   1.22   3.9 × 10^−6^   1.23   6.2 × 10^−5^   1.26

\* Association analyses of SNPs were performed using case and control data from the original ImmunoChip discovery cohort, the validation cohorts (UK and US), and the meta-analysis (ImmunoChip and validation cohorts). OR = odds ratio.

Validation *P* value is presented for each SNP in the same stratification as that in the discovery study.
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In the meta-analysis, 1 SNP, rs7535176, showed evidence of high heterogeneity between studies (I^2^ = 57%), and was therefore removed from further analysis. In power calculations, the average power to detect the likelihood of an association with RA at an OR of 1.12 (*P* = 5 × 10^−8^) was 81% in the overall validation study, 41% in the anti-CCP--positive RA subset, and 6% in the anti-CCP--negative RA subset, based on an average MAF of 0.19.

DISCUSSION
==========

Of the 12 loci assessed for an association with susceptibility to RA in the validation study, 2 reached accepted genome-wide significance thresholds either in the RA group as a whole or in the subset with anti-CCP antibodies, indicating that these 2 loci (*BACH2, RAD51B*) represent novel RA susceptibility loci. A further 4 SNPs showed evidence for validation of an association at a significance level of *P* \< 0.05 (*COG6, PVT1*, *PTPN2,* and *TNFSF4*). All of the loci assessed showed effect sizes in the same direction as those in the original ImmunoChip discovery study. Of the newly confirmed RA susceptibility SNPs, rs72928038 maps to an intron of *BACH2* (6q15), which has previously been associated with type 1 diabetes ([@b9]), Crohn\'s disease ([@b10]), and celiac disease ([@b11]). *BACH2* encodes BTB and CNC homology 1, basic leucine zipper transcription factor 2, a B cell--specific transcription factor that has been shown to regulate the *BLIMP1* gene (also known as *PRDM1*, a validated RA susceptibility locus) in mice, which in turn influences plasma cell differentiation and promotes the antibody class switch ([@b12]). Rituximab, an effective RA treatment, inhibits CD20+ B cells, a cell subtype in which *BACH2* is highly expressed.

The second novel SNP associated with RA, rs911263, was found to be significantly associated with RA risk in the anti-CCP--positive subgroup (*P*~anti-CCP+\ meta-analysis~ = 4 × 10^−8^) but not in the anti-CCP--negative subgroup (*P*~anti-CCP−\ meta-analysis~ = 0.45). This SNP maps to an intron in *RAD51B* (14q24), which has recently been found to be associated with primary biliary cirrhosis ([@b13]). *RAD51B* is a gene involved in the homologous recombination repair pathway of double-stranded DNA breaks. It has been demonstrated that anti-CCP--positive and anti-CCP--negative disease have differing allelic associations at the HLA locus, and identification of an association of *RAD51B* with anti-CCP--positive RA may add to the list of genes that differentiate between the disease subgroups, although this could not be formally proven in the present study because of the reduced power in the anti-CCP--negative cohort.

An association of 4 loci (*COG6, PVT1, PTPN2,* and *TNFSF4*) with RA risk was replicated in the validation study, at *P* \< 0.05, but none reached genome-wide significance in the overall analysis. Given that these loci are associated with multiple autoimmune diseases, there is strong a priori evidence that these are likely to be RA susceptibility loci. Indeed, an association of RA risk with *PTPN2* has now reached genome-wide significance levels, as demonstrated in an expanded, independent analysis in a European cohort ([@b14]).

The number of SNPs with suggestive evidence from the ImmunoChip analysis suggests that there are many additional undiscovered risk alleles with modest effect sizes that have yet to be formally confirmed at genome-wide significance levels of association. Power calculations showed the necessity of larger sample sizes to detect the more modest effect sizes detected in this second tier of significance, indicating that there is still great value in increasing study size to identify novel susceptibility loci. Indeed, combined sample sizes of more than 75,000 cases and controls were required to identify the 163 loci now confirmed to be associated with IBD. Sample size and power therefore remain a limitation in our current study, in particular with respect to the lack of data on the ACPA status of patients in the validation cohorts. A further limitation in this study was the targeted SNP genotyping, chosen as a cost-effective strategy to confirm putative associations. By adopting this strategy, our capacity to fine map the newly identified loci was restricted to data generated in the ImmunoChip experiment.

In conclusion, we obtained convincing evidence of 2 new RA susceptibility loci, *BACH2* and *RAD51B*, in a combined meta-analysis of 17,581 cases and 20,160 controls, bringing the total number of novel RA susceptibility loci identified in Caucasians to 48. These findings implicate 2 distinct biologic pathways, those of B cell differentiation and DNA repair, in serologic subtypes of RA. Identification of all genetic variants that predispose to RA will increase our understanding of the molecular mechanisms involved and better annotate biologic pathway analyses.
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